Genetic test to guide antiplatelet treatment for heart patients
Part of Heart & circulation clinical trials.
This trial tests whether a genetic test can help doctors choose the best blood-thinning medicine for people with heart disease who are having a stent placed. The goal is to reduce the risk of blood clots or bleeding after the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stable heart disease or a recent heart attack (acute coronary syndrome).
- You are scheduled to have a stent placed in a heart artery (PCI).
- You agree to provide a blood sample for genetic testing and to have your platelets checked.
- You are willing to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This trial tests whether using a rapid genetic test to choose antiplatelet medication can improve outcomes for people who have had a stroke or mini-stroke. The test checks a gene that affects how your body processes a common antiplatelet drug, so your doctors can pick the safest and most effective medicine for you.
This trial looks at whether using clopidogrel by itself (without aspirin) works for people after a new drug-eluting stent, based on a blood test of how your body processes the drug. It may help reduce “extra blood-thinning” if you have a certain genetic type that responds well to clopidogrel.
This trial compares using a genetic test to choose between two anti-clot medications (clopidogrel and ticagrelor) versus the usual approach of giving clopidogrel alone. It aims to see if personalized treatment can better prevent strokes in people with narrowed brain arteries.
This study tests whether switching early to a weaker anti-platelet medicine based on your genetics can reduce bleeding problems in people at high risk for bleeding after a heart attack. It compares this approach to the usual strategy of staying on a stronger anti-platelet medicine.
This study tests whether tailoring blood-thinner medication based on a cheek swab can improve recovery after having a heart stent placed. Participants will be randomly assigned to one of two blood thinners, and their treatment will be adjusted based on genetic testing.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.